Document is current
Any future updates will be listed below
-
Authors
Globig, Anna-Maria http://orcid.org/0000-0002-5236-7459
Zhao, Steven http://orcid.org/0000-0002-8102-8368
Roginsky, Jessica http://orcid.org/0000-0002-1174-8423
Maltez, Vivien I.
Guiza, Juan http://orcid.org/0000-0002-3843-5048
Avina-Ochoa, Natalia http://orcid.org/0000-0002-5804-8766
Heeg, Maximilian http://orcid.org/0000-0002-9594-1377
Araujo Hoffmann, Filipe
Chaudhary, Omkar
Wang, Jiawei http://orcid.org/0000-0003-2627-4897
Senturk, Gokhan http://orcid.org/0000-0002-7005-9644
Chen, Dan
O’Connor, Carolyn
Pfaff, Samuel http://orcid.org/0000-0002-2142-166X
Germain, Ronald N. http://orcid.org/0000-0003-1495-9143
Schalper, Kurt A. http://orcid.org/0000-0001-5692-4833
Emu, Brinda
Kaech, Susan M. http://orcid.org/0000-0003-1674-1420
- License Information
-
More Information
Article History
Received: 26 September 2022
Accepted: 24 August 2023
First Online: 20 September 2023
Competing interests
: S.M.K. is a scientific advisory board member for Pfizer, EvolveImmune Therapeutics, Arvinas and Affini-T, and an Academic Editor at the <i>Journal of Experimental Medicine</i>. K.A.S. has received honoraria for consulting/advisory board or speaker from Clinica Alemana Santiago, Shattuck Labs, AstraZeneca, EMD Serono, Takeda, Torque/Repertoire Therapeutics, Agenus, Genmab, OnCusp, Parthenon Therapeutics, CDRlife, Bristol-Myers Squibb, Roche, Molecular Templates, PeerView, Forefront Collaborative, Janssen and Merck. The K.A.S. Laboratory at Yale University receives funding from Tesaro/GSK, Takeda, Merck, Bristol-Myers Squibb, AstraZeneca, Ribon Therapeutics, Boehringer-Ingelheim and Roche. The remaining authors declare no conflicts of interest.
